Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Feb;53(2):137–147. doi: 10.1136/thx.53.2.137

New therapies for chronic obstructive pulmonary disease

P J Barnes
PMCID: PMC1758707  PMID: 9624300

Full Text

The Full Text of this article is available as a PDF (149.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbinante-Nissen J. M., Simpson L. G., Leikauf G. D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol. 1995 Apr;268(4 Pt 1):L601–L606. doi: 10.1152/ajplung.1995.268.4.L601. [DOI] [PubMed] [Google Scholar]
  2. Adams D. H., Lloyd A. R. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 1997 Feb 15;349(9050):490–495. doi: 10.1016/s0140-6736(96)07524-1. [DOI] [PubMed] [Google Scholar]
  3. Alabaster V. A. Discovery & development of selective M3 antagonists for clinical use. Life Sci. 1997;60(13-14):1053–1060. doi: 10.1016/s0024-3205(97)00047-7. [DOI] [PubMed] [Google Scholar]
  4. Anderson R., Theron A. J., Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation. 1996 Dec;20(6):693–705. doi: 10.1007/BF01488805. [DOI] [PubMed] [Google Scholar]
  5. Anthonisen N. R., Connett J. E., Kiley J. P., Altose M. D., Bailey W. C., Buist A. S., Conway W. A., Jr, Enright P. L., Kanner R. E., O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed] [Google Scholar]
  6. Barnes P. J., Belvisi M. G., Mak J. C., Haddad E. B., O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 1995;56(11-12):853–859. doi: 10.1016/0024-3205(95)00020-7. [DOI] [PubMed] [Google Scholar]
  7. Barnes P. J. Endothelins and pulmonary diseases. J Appl Physiol (1985) 1994 Sep;77(3):1051–1059. doi: 10.1152/jappl.1994.77.3.1051. [DOI] [PubMed] [Google Scholar]
  8. Barnes P. J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997 Apr 10;336(15):1066–1071. doi: 10.1056/NEJM199704103361506. [DOI] [PubMed] [Google Scholar]
  9. Bernstein P. R., Edwards P. D., Williams J. C. Inhibitors of human leukocyte elastase. Prog Med Chem. 1994;31:59–120. doi: 10.1016/s0079-6468(08)70019-5. [DOI] [PubMed] [Google Scholar]
  10. Bloemen P. G., van den Tweel M. C., Henricks P. A., Engels F., Kester M. H., van de Loo P. G., Blomjous F. J., Nijkamp F. P. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol. 1997 Apr;272(4 Pt 1):L580–L587. doi: 10.1152/ajplung.1997.272.4.L580. [DOI] [PubMed] [Google Scholar]
  11. Boman G., Bäcker U., Larsson S., Melander B., Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983 Aug;64(6):405–415. [PubMed] [Google Scholar]
  12. Bosken C. H., Hards J., Gatter K., Hogg J. C. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):911–917. doi: 10.1164/ajrccm/145.4_Pt_1.911. [DOI] [PubMed] [Google Scholar]
  13. Boyd G., Morice A. H., Pounsford J. C., Siebert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997 Apr;10(4):815–821. [PubMed] [Google Scholar]
  14. Cadène M., Duranton J., North A., Si-Tahar M., Chignard M., Bieth J. G. Inhibition of neutrophil serine proteinases by suramin. J Biol Chem. 1997 Apr 11;272(15):9950–9955. doi: 10.1074/jbc.272.15.9950. [DOI] [PubMed] [Google Scholar]
  15. Cazzola M., Matera M. G., Santangelo G., Vinciguerra A., Rossi F., D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995 May;89(5):357–362. doi: 10.1016/0954-6111(95)90008-x. [DOI] [PubMed] [Google Scholar]
  16. Claman D. M., Boushey H. A., Liu J., Wong H., Fahy J. V. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol. 1994 Nov;94(5):861–869. doi: 10.1016/0091-6749(94)90154-6. [DOI] [PubMed] [Google Scholar]
  17. Cohen A. B., Girard W., Mclarty J., Starcher B., Stevens M., Fair D. S., Davis D., James H., Rosenbloom J., Kucich U. A controlled trial of colchicine to reduce the elastase load in the lungs of cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990 Jul;142(1):63–72. doi: 10.1164/ajrccm/142.1.63. [DOI] [PubMed] [Google Scholar]
  18. Dekhuijzen P. N., Aben K. K., Dekker I., Aarts L. P., Wielders P. L., van Herwaarden C. L., Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):813–816. doi: 10.1164/ajrccm.154.3.8810624. [DOI] [PubMed] [Google Scholar]
  19. Disse B., Reichl R., Speck G., Traunecker W., Ludwig Rominger K. L., Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5-6):537–544. doi: 10.1016/0024-3205(93)90312-q. [DOI] [PubMed] [Google Scholar]
  20. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  21. Evans D. J., Barnes P. J., Spaethe S. M., van Alstyne E. L., Mitchell M. I., O'Connor B. J. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax. 1996 Dec;51(12):1178–1184. doi: 10.1136/thx.51.12.1178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Finkelstein R., Fraser R. S., Ghezzo H., Cosio M. G. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1666–1672. doi: 10.1164/ajrccm.152.5.7582312. [DOI] [PubMed] [Google Scholar]
  23. Finlay G. A., Russell K. J., McMahon K. J., D'arcy E. M., Masterson J. B., FitzGerald M. X., O'Connor C. M. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997 Jun;52(6):502–506. doi: 10.1136/thx.52.6.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Foulds J. Strategies for smoking cessation. Br Med Bull. 1996 Jan;52(1):157–173. doi: 10.1093/oxfordjournals.bmb.a011523. [DOI] [PubMed] [Google Scholar]
  25. Gendler S. J., Spicer A. P. Epithelial mucin genes. Annu Rev Physiol. 1995;57:607–634. doi: 10.1146/annurev.ph.57.030195.003135. [DOI] [PubMed] [Google Scholar]
  26. Goswami S. K., Kivity S., Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis. 1990 Jan;141(1):72–78. doi: 10.1164/ajrccm/141.1.72. [DOI] [PubMed] [Google Scholar]
  27. Haddad E. B., Mak J. C., Barnes P. J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994 May;45(5):899–907. [PubMed] [Google Scholar]
  28. Hautamaki R. D., Kobayashi D. K., Senior R. M., Shapiro S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997 Sep 26;277(5334):2002–2004. doi: 10.1126/science.277.5334.2002. [DOI] [PubMed] [Google Scholar]
  29. Hohlfeld J., Fabel H., Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J. 1997 Feb;10(2):482–491. doi: 10.1183/09031936.97.10020482. [DOI] [PubMed] [Google Scholar]
  30. Hubbard R. C., Crystal R. G. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168 (Suppl):565–578. doi: 10.1007/BF02718179. [DOI] [PubMed] [Google Scholar]
  31. Hubbard R. C., Fells G., Gadek J., Pacholok S., Humes J., Crystal R. G. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest. 1991 Sep;88(3):891–897. doi: 10.1172/JCI115391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C., Khayrallah M. A., Schroeder D. R., Glover P. N., Sullivan C. R. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 Oct 23;337(17):1195–1202. doi: 10.1056/NEJM199710233371703. [DOI] [PubMed] [Google Scholar]
  33. Ichikawa Y., Ninomiya H., Koga H., Tanaka M., Kinoshita M., Tokunaga N., Yano T., Oizumi K. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis. 1992 Jul;146(1):196–203. doi: 10.1164/ajrccm/146.1.196. [DOI] [PubMed] [Google Scholar]
  34. Kawabata K., Suzuki M., Sugitani M., Imaki K., Toda M., Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177(2):814–820. doi: 10.1016/0006-291x(91)91862-7. [DOI] [PubMed] [Google Scholar]
  35. Keatings V. M., Collins P. D., Scott D. M., Barnes P. J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):530–534. doi: 10.1164/ajrccm.153.2.8564092. [DOI] [PubMed] [Google Scholar]
  36. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  37. Kiely D. G., Cargill R. I., Wheeldon N. M., Coutie W. J., Lipworth B. J. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res. 1997 Jan;33(1):201–208. doi: 10.1016/s0008-6363(96)00180-0. [DOI] [PubMed] [Google Scholar]
  38. Kwon O. J., Au B. T., Collins P. D., Adcock I. M., Mak J. C., Robbins R. R., Chung K. F., Barnes P. J. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am J Physiol. 1994 Oct;267(4 Pt 1):L398–L405. doi: 10.1152/ajplung.1994.267.4.L398. [DOI] [PubMed] [Google Scholar]
  39. Kwon O. J., Au B. T., Collins P. D., Baraniuk J. N., Adcock I. M., Chung K. F., Barnes P. J. Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. Immunology. 1994 Mar;81(3):389–394. [PMC free article] [PubMed] [Google Scholar]
  40. Lacoste J. Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., Vic P., Enander I., Godard P., Michel F. B. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993 Oct;92(4):537–548. doi: 10.1016/0091-6749(93)90078-t. [DOI] [PubMed] [Google Scholar]
  41. Lief H. I. Bupropion treatment of depression to assist smoking cessation. Am J Psychiatry. 1996 Mar;153(3):442–442. doi: 10.1176/ajp.153.3.442a. [DOI] [PubMed] [Google Scholar]
  42. Llewellyn-Jones C. G., Harris T. A., Stockley R. A. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med. 1996 Feb;153(2):616–621. doi: 10.1164/ajrccm.153.2.8564107. [DOI] [PubMed] [Google Scholar]
  43. Llewellyn-Jones C. G., Johnson M. M., Mitchell J. L., Pye A., Okafor V. C., Hill S. L., Stockley R. A. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J. 1995 Sep;8(9):1479–1487. [PubMed] [Google Scholar]
  44. Llewellyn-Jones C. G., Lomas D. A., Stockley R. A. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax. 1994 Jun;49(6):567–572. doi: 10.1136/thx.49.6.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Llewellyn-Jones C. G., Stockley R. A. The effects of beta 2-agonists and methylxanthines on neutrophil function in vitro. Eur Respir J. 1994 Aug;7(8):1460–1466. doi: 10.1183/09031936.94.07081460. [DOI] [PubMed] [Google Scholar]
  46. Luisetti M., Sturani C., Sella D., Madonini E., Galavotti V., Bruno G., Peona V., Kucich U., Dagnino G., Rosenbloom J. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J. 1996 Jul;9(7):1482–1486. doi: 10.1183/09031936.96.09071482. [DOI] [PubMed] [Google Scholar]
  47. Maesen F. P., Smeets J. J., Sledsens T. J., Wald F. D., Cornelissen P. J. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995 Sep;8(9):1506–1513. [PubMed] [Google Scholar]
  48. Marom Z. M., Goswami S. K. Respiratory mucus hypersecretion (bronchorrhea): a case discussion--possible mechanisms(s) and treatment. J Allergy Clin Immunol. 1991 Jun;87(6):1050–1055. doi: 10.1016/0091-6749(91)92149-u. [DOI] [PubMed] [Google Scholar]
  49. Martin T. R., Pistorese B. P., Chi E. Y., Goodman R. B., Matthay M. A. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest. 1989 Nov;84(5):1609–1619. doi: 10.1172/JCI114338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Massaro G. D., Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997 Jun;3(6):675–677. doi: 10.1038/nm0697-675. [DOI] [PubMed] [Google Scholar]
  51. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  52. McEvoy C. E., Niewoehner D. E. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest. 1997 Mar;111(3):732–743. doi: 10.1378/chest.111.3.732. [DOI] [PubMed] [Google Scholar]
  53. Miyajima T., Kotake Y. Spin trapping agent, phenyl N-tert-butyl nitrone, inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biochem Biophys Res Commun. 1995 Oct 4;215(1):114–121. doi: 10.1006/bbrc.1995.2440. [DOI] [PubMed] [Google Scholar]
  54. Mueller R., Chanez P., Campbell A. M., Bousquet J., Heusser C., Bullock G. R. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med. 1996 Feb;90(2):79–85. doi: 10.1016/s0954-6111(96)90202-4. [DOI] [PubMed] [Google Scholar]
  55. Müller T., Engels P., Fozard J. R. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci. 1996 Aug;17(8):294–298. doi: 10.1016/0165-6147(96)10035-3. [DOI] [PubMed] [Google Scholar]
  56. Nielson C. P., Vestal R. E., Sturm R. J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990 Nov;86(5):801–808. doi: 10.1016/s0091-6749(05)80186-1. [DOI] [PubMed] [Google Scholar]
  57. O'Shaughnessy T. C., Ansari T. W., Barnes N. C., Jeffery P. K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997 Mar;155(3):852–857. doi: 10.1164/ajrccm.155.3.9117016. [DOI] [PubMed] [Google Scholar]
  58. Oetomo S. B., Lewis J., Ikegami M., Jobe A. H. Surfactant treatments alter endogenous surfactant metabolism in rabbit lungs. J Appl Physiol (1985) 1990 Apr;68(4):1590–1596. doi: 10.1152/jappl.1990.68.4.1590. [DOI] [PubMed] [Google Scholar]
  59. Okano Y., Yoshioka T., Shimouchi A., Satoh T., Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997 May 10;349(9062):1365–1365. doi: 10.1016/S0140-6736(97)24019-5. [DOI] [PubMed] [Google Scholar]
  60. Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996 May 1;124(9):820–824. doi: 10.7326/0003-4819-124-9-199605010-00006. [DOI] [PubMed] [Google Scholar]
  61. Pepke-Zaba J., Higenbottam T. W., Dinh-Xuan A. T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991 Nov 9;338(8776):1173–1174. doi: 10.1016/0140-6736(91)92033-x. [DOI] [PubMed] [Google Scholar]
  62. Posner J., Dean K., Jeal S., Moody S. G., Peck A. W., Rutter G., Telekes A. A preliminary study of the pharmacodynamics and pharmacokinetics of a novel enkephalin analogue [Tyr-D.Arg-Gly-Phe (4NO2).Pro.NH2 (BW443C)] in healthy volunteers. Eur J Clin Pharmacol. 1988;34(1):67–71. doi: 10.1007/BF01061420. [DOI] [PubMed] [Google Scholar]
  63. Ramnarine S. I., Hirayama Y., Barnes P. J., Rogers D. F. 'Sensory-efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. Br J Pharmacol. 1994 Dec;113(4):1183–1190. doi: 10.1111/j.1476-5381.1994.tb17122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Renkema T. E., Schouten J. P., Koëter G. H., Postma D. S. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996 May;109(5):1156–1162. doi: 10.1378/chest.109.5.1156. [DOI] [PubMed] [Google Scholar]
  65. Repine J. E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):341–357. doi: 10.1164/ajrccm.156.2.9611013. [DOI] [PubMed] [Google Scholar]
  66. Rogers D. F., Aursudkij B., Barnes P. J. Effects of tachykinins on mucus secretion in human bronchi in vitro. Eur J Pharmacol. 1989 Dec 19;174(2-3):283–286. doi: 10.1016/0014-2999(89)90322-1. [DOI] [PubMed] [Google Scholar]
  67. Rogers D. F., Barnes P. J. Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1989 Apr 29;1(8644):930–932. doi: 10.1016/s0140-6736(89)92509-9. [DOI] [PubMed] [Google Scholar]
  68. Saetta M., Di Stefano A., Maestrelli P., Ferraresso A., Drigo R., Potena A., Ciaccia A., Fabbri L. M. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993 Feb;147(2):301–306. doi: 10.1164/ajrccm/147.2.301. [DOI] [PubMed] [Google Scholar]
  69. Saetta M., Di Stefano A., Maestrelli P., Turato G., Ruggieri M. P., Roggeri A., Calcagni P., Mapp C. E., Ciaccia A., Fabbri L. M. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1646–1652. doi: 10.1164/ajrccm.150.6.7952628. [DOI] [PubMed] [Google Scholar]
  70. Sallenave J. M., Shulmann J., Crossley J., Jordana M., Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994 Dec;11(6):733–741. doi: 10.1165/ajrcmb.11.6.7946401. [DOI] [PubMed] [Google Scholar]
  71. Sandford A. J., Weir T. D., Paré P. D. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997 Jun;10(6):1380–1391. doi: 10.1183/09031936.97.10061380. [DOI] [PubMed] [Google Scholar]
  72. Schneider N. G., Olmstead R. E., Steinberg C., Sloan K., Daims R. M., Brown H. V. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther. 1996 Nov;60(5):568–575. doi: 10.1016/S0009-9236(96)90153-8. [DOI] [PubMed] [Google Scholar]
  73. Schudt C., Winder S., Forderkunz S., Hatzelmann A., Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol. 1991 Dec;344(6):682–690. doi: 10.1007/BF00174752. [DOI] [PubMed] [Google Scholar]
  74. Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A., Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997 Oct;10(10):2260–2263. doi: 10.1183/09031936.97.10102260. [DOI] [PubMed] [Google Scholar]
  75. Shah P. L., Scott S. F., Knight R. A., Marriott C., Ranasinha C., Hodson M. E. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax. 1996 Feb;51(2):119–125. doi: 10.1136/thx.51.2.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Silagy C., Mant D., Fowler G., Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994 Jan 15;343(8890):139–142. doi: 10.1016/s0140-6736(94)90933-4. [DOI] [PubMed] [Google Scholar]
  77. Smith C. A., Harrison D. J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997 Aug 30;350(9078):630–633. doi: 10.1016/S0140-6736(96)08061-0. [DOI] [PubMed] [Google Scholar]
  78. Smith S. F., Roberts N. A., Guz A., Tetley T. D. Compromised inhibition of human lung lavage cell elastases. FEBS Lett. 1996 Jul 22;390(2):187–190. doi: 10.1016/0014-5793(96)00655-2. [DOI] [PubMed] [Google Scholar]
  79. Sofia M., Mormile M., Faraone S., Carratù P., Alifano M., Di Benedetto G., Carratù L. Increased 24-hour endothelin-1 urinary excretion in patients with chronic obstructive pulmonary disease. Respiration. 1994;61(5):263–268. doi: 10.1159/000196349. [DOI] [PubMed] [Google Scholar]
  80. Sommerhoff C. P., Krell R. D., Williams J. L., Gomes B. C., Strimpler A. M., Nadel J. A. Inhibition of human neutrophil elastase by ICI 200,355. Eur J Pharmacol. 1991 Feb 7;193(2):153–158. doi: 10.1016/0014-2999(91)90030-t. [DOI] [PubMed] [Google Scholar]
  81. Sommerhoff C. P., Nadel J. A., Basbaum C. B., Caughey G. H. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest. 1990 Mar;85(3):682–689. doi: 10.1172/JCI114492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Takahashi T., Belvisi M. G., Patel H., Ward J. K., Tadjkarimi S., Yacoub M. H., Barnes P. J. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1640–1645. doi: 10.1164/ajrccm.150.6.7952627. [DOI] [PubMed] [Google Scholar]
  83. Talpain E., Armstrong R. A., Coleman R. A., Vardey C. J. Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br J Pharmacol. 1995 Apr;114(7):1459–1465. doi: 10.1111/j.1476-5381.1995.tb13370.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Tamaoki J., Chiyotani A., Kobayashi K., Sakai N., Kanemura T., Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis. 1992 Mar;145(3):548–552. doi: 10.1164/ajrccm/145.3.548. [DOI] [PubMed] [Google Scholar]
  85. Tamaoki J., Nakata J., Takeyama K., Chiyotani A., Konno K. Histamine H2 receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes. J Allergy Clin Immunol. 1997 Feb;99(2):233–238. doi: 10.1016/s0091-6749(97)70102-7. [DOI] [PubMed] [Google Scholar]
  86. Thomas C. E., Ohlweiler D. F., Carr A. A., Nieduzak T. R., Hay D. A., Adams G., Vaz R., Bernotas R. C. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem. 1996 Feb 9;271(6):3097–3104. doi: 10.1074/jbc.271.6.3097. [DOI] [PubMed] [Google Scholar]
  87. Thompson A. B., Daughton D., Robbins R. A., Ghafouri M. A., Oehlerking M., Rennard S. I. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis. 1989 Dec;140(6):1527–1537. doi: 10.1164/ajrccm/140.6.1527. [DOI] [PubMed] [Google Scholar]
  88. Thompson W. H., Nielson C. P., Carvalho P., Charan N. B., Crowley J. J. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407–412. doi: 10.1164/ajrccm.154.2.8756814. [DOI] [PubMed] [Google Scholar]
  89. Turato G., Di Stefano A., Maestrelli P., Mapp C. E., Ruggieri M. P., Roggeri A., Fabbri L. M., Saetta M. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1262–1267. doi: 10.1164/ajrccm.152.4.7551380. [DOI] [PubMed] [Google Scholar]
  90. Ulrik C. S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax. 1995 Jul;50(7):750–754. doi: 10.1136/thx.50.7.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996 May;153(5):1530–1535. doi: 10.1164/ajrccm.153.5.8630597. [DOI] [PubMed] [Google Scholar]
  92. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest New Drugs. 1997;15(1):61–75. doi: 10.1023/a:1005722729132. [DOI] [PubMed] [Google Scholar]
  93. Zakrzewski J. T., Barnes N. C., Costello J. F., Piper P. J. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987 Sep;136(3):779–782. doi: 10.1164/ajrccm/136.3.779. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES